Developed for the pharmacy sector, Canabidol™ products meet the exacting standards required by pharmacists for the retail sale of CBD. One of the longest standing brands in the UK, Canabidol™ has spearheaded the industry with it our dedication to excellence, passion for compliance and commitment to getting things right. The result has seen Canabidol™ products become the market leading brand in the pharmacy sector, with thousands of customers preferring Canabidol™. Which is now the only brand of choice in the UK, it’s the reason our thousands of registered official resellers now stock our products in high streets and major retail outlets across the country.
Nabiximols (brand name Sativex) is a patented medicine containing CBD and THC in equal proportions. The drug was approved by Health Canada in 2005 for prescription to treat central neuropathic pain in multiple sclerosis, and in 2007 for cancer related pain. In New Zealand, Sativex is "approved for use as an add-on treatment for symptom improvement in people with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication."
Everything you need to know about marijuana (cannabis) Marijuana, or cannabis, is the most commonly used illicit drug in the world. It alters the mood and affects nearly every organ in the body. With at least 120 active compounds, marijuana may have health benefits as well as risks. We describe these, addiction, and withdrawal. Learn more about cannabis here. Read now
In nature, Cannabis ruderalis typically has the lowest levels of THC, Cannabis sativa has a higher level of THC than it has CBD, and Cannabis indica has a higher level of CBD than it has THC. However, since man has been cultivating cannabis (and especially Cannabis sativa) for thousands of years, the effects of artificial selections have led to several different types of cannabis even within the same species, depending on the purpose the cannabis was cultivated for.
Until relatively recently (1980s), scientists believed that CBD was a natural precursor to the formation of THC, and since THC was a strictly controlled substance back then (it still is), it only followed that CBD should be equally strictly regulated. However, CBD is actually unrelated to the chemical chain that results in THC. They share some characteristics but are created via different paths. Again, unlike THC, CBD is considered a legal cannabinoid and is safe to consume in any amount and concentration.
Laboratory evidence indicated that cannabidiol may reduce THC clearance, increasing plasma concentrations which may raise THC availability to receptors and enhance its effect in a dose-dependent manner. In vitro, cannabidiol inhibited receptors affecting the activity of voltage-dependent sodium and potassium channels, which may affect neural activity. A small clinical trial reported that CBD partially inhibited the CYP2C-catalyzed hydroxylation of THC to 11-OH-THC. Little is known about potential drug interactions, but CBD-mediates a decrease in clobazam metabolism.
Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Novakova, I., Zapletalova, O., Pikova, J., and Ambler, Z. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol.Res. 2010;32(5):451-459. View abstract.
Schizophrenia. Research on the use of cannabidiol for psychotic symptoms in people with schizophrenia is conflicting. Some early research suggests that taking cannabidiol four times daily for 4 weeks improves psychotic symptoms and might be as effective as the antipsychotic medication amisulpride. However, other early research suggests that taking cannabidiol for 14 days is not beneficial. The conflicting results might be related to the cannabidiol dose used and duration of treatment. cannabidiol oil